

# Can vitamin D improve symptoms and quality of life in people with irritable bowel syndrome (IBS)?

<b>Submission date</b> 23/03/2018	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 25/04/2018	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 02/08/2021	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Irritable bowel syndrome (IBS) is a common condition that affects the digestive system. IBS is usually experienced for a life-time and symptoms include bloating, constipation, diarrhoea, and stomach cramps. These symptoms can affect a person for days, weeks or even months at a time. This can be a difficult condition to live with and can have a large impact on a person's everyday life. The cause of IBS is unknown, although it is thought to be associated with a family history of IBS, stress and certain foods. IBS cannot be cured but can often be managed with medication and dietary changes. Research has shown that people with IBS also have low levels of vitamin D. The aim of this study is to assess whether increasing vitamin D levels in people with IBS helps to improve their symptoms.

### Who can participate?

Men and women aged between 18-60 years with a diagnosis of IBS

### What does the study involve?

Each person will be put into one of two groups to receive either a vitamin D or placebo (dummy) supplement mouth spray to be taken each day for 12 weeks. All participants will be asked to fill in a total of seven Symptom Severity Questionnaires (SSS-IBS), two Quality of Life Questionnaires (QoL), and one Food Frequency Questionnaire (FFQ). All participants will have blood samples taken at the first and last appointment. This will be done with a finger prick blood test kit. All participants will take a mouth spray, only half of the volunteers will get the active (real) vitamin D supplement.

### What are the possible benefits and risks of participating?

The supplement that participants will be taking are well under the advised limit, however, there is a very unlikely risk of vitamin D levels going too high. Side effects of excessive vitamin D levels include raised calcium blood levels, nausea and constipation. Participants will be monitored closely for any problems they may experience during the study. There will also be small risks involved with taking blood samples, such as pain around the site of insertion, as with any blood test. These risks will be clearly explained to the participants. The

finger prick only occurs twice; at the start and end of the 12 weeks. Volunteers on the active (real) supplement may benefit from their participation in the research as they may see an improvement in their symptoms and all volunteers will receive a £50.00 voucher as a thank you for their participation.

Where is the study run from?

This study will be run from the Medical School at the University of Sheffield.

When is the study starting and how long is it expected to run for?

Recruitment will occur three times over the next 2 years. The first two rounds will occur in the winter periods (Jan-Apr) in 2018 and 2019 in the local area with the goal of reaching 160 volunteers. A further recruitment will take place in 2019 to recruit volunteers from outside the local area and will use postal and online methods to complete the research. The anticipated start date of the trial is September 2018 and will run until September 2020.

Who is funding the study?

This research has been part funded by the University of Sheffield and by an industry partner BetterYou.

Who is the main contact?

The main person to contact regarding this study is Dr Bernard Corfe, Senior Lecturer in Oncology Principal Investigator in Molecular Gastroenterology, Fellow of Insigneo, b.m.corfe@sheffield.ac.uk.

## Contact information

### Type(s)

Scientific

### Contact name

Dr Bernard Corfe

### Contact details

The University of Sheffield  
The Medical School  
Beech Hill Road  
Sheffield  
S10 2RX  
United Kingdom  
Sheffield  
United Kingdom  
S10 2RX

### Type(s)

Public

### Contact name

Mrs Claire Williams

### Contact details

The Medical School  
Beech Hill Road  
Sheffield  
S10 2RX  
United Kingdom  
Sheffield  
United Kingdom  
S10 2RX  
07925034693  
cewilliams1@sheffield.ac.uk

## **Additional identifiers**

### **Protocol serial number**

016753

## **Study information**

### **Scientific Title**

To assess whether an increase of vitamin D in subjects with irritable bowel syndrome improves symptoms (D-IBS)

### **Acronym**

D-IBS

### **Study objectives**

The hypothesis is that a 3000 IU vitamin D supplement will reduce symptom severity and improve quality of life compared with placebo in participants with IBS, based on self-reported outcomes.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

University of Sheffield, 19/12/2017, Registration number: 160216727, Reference Number: 016753

### **Study design**

Double-blind placebo-controlled two-arm parallel-design study

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Irritable bowel syndrome

### **Interventions**

Patients administered 3000 IU (75 microg) vitamin D sublingual spray or placebo sublingual spray once daily for 12 weeks

### **Intervention Type**

Supplement

### **Primary outcome(s)**

Reduction in Total Symptom Severity for IBS, measured by visual analogue scale (VAS) at baseline and exit, and a cumulative measure taken fortnightly across the intervention period (weeks 0, 2, 4, 6, 8, 10, 12).

### **Key secondary outcome(s)**

1. Serum vitamin D concentrations will be assessed at baseline and exit: bloodspots will be taken and analysed by liquid chromatography-mass spectrometry .
2. Quality of life is assessed at baseline and exit using The Irritable Bowel Syndrome - Quality of Life questionnaire (IBS-QOL)

### **Completion date**

30/09/2020

## **Eligibility**

### **Key inclusion criteria**

Clinical diagnosis of IBS using the ROME criteria and reaching severity score of 150 on SSS scale at time of recruitment. As some participants may have active IBS but historic diagnosis, no one version of ROME is specified as long as a clinical diagnosis was made at the time.

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Sex**

All

### **Total final enrolment**

135

### **Key exclusion criteria**

1. Pregnant or lactating
2. Regular use of nutritional supplements
3. BMI >30 kg/m<sup>2</sup>
4. BMI <18 kg/m<sup>2</sup>
5. Any history of gastrointestinal disorders (Crohn's disease, ulcerative colitis, diverticulitis)
6. Diabetes mellitus

**Date of first enrolment**

08/01/2018

**Date of final enrolment**

30/07/2020

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**The University of Sheffield**

The Medical School

Beech Hill Road

Sheffield

S10 2RX

United Kingdom

Sheffield

United Kingdom

S10 2RX

## Sponsor information

**Organisation**

The University of Sheffield

**ROR**

<https://ror.org/05krs5044>

## Funder(s)

**Funder type**

Not defined

**Funder Name**

BetterYou

## Funder Name

The University of Sheffield

# Results and Publications

## Individual participant data (IPD) sharing plan

As there are no repositories for trial data, we will share an annotated, anonymised spreadsheet on request following publication of any papers.

## IPD sharing plan summary

Data sharing statement to be made available at a later date

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		30/07/2021	02/08/2021	Yes	No